MB-101: Phase I data

Data from the first dose level of an investigator-led, open-label, dose-escalation, U.S. Phase I trial showed that MB-101 led to a complete response

Read the full 233 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE